The Lancet 'Under Review': Status Meanings, Timelines, and What to Expect

The Lancet's desk rejection rate is among the highest in academic publishing. Senior editors evaluate three things in roughly this order:

1. Global health significance. More than any other top medical journal, Lancet prioritizes research with implications for global health. Studies that address health equity, populations in low- and middle-income countries, or diseases of global burden get editorial attention. A perfectly designed trial of a first-world disease with limited global relevance may not pass the desk.

2. Practice-changing potential. Will this study change clinical guidelines? Will health policymakers reference it? The Lancet wants research that moves the needle on how medicine is practiced at scale.

3. Methodological strength. Large, well-designed clinical trials, prospective cohort studies, and systematic reviews with strong methodology. The Lancet expects statistical rigor and adequate power for the claims being made.

If your paper cleared this screen, the editors believe it has genuine Lancet-level significance. That's a meaningful signal.

Once your paper moves to Under Review, the Lancet editor assigns 2-3 reviewers. The reviewer selection process is careful:

• Reviewers have direct expertise in your clinical area
• They don't have conflicts of interest with your research group
• Lancet tries to include at least one reviewer from a different geographic region than the authors

Reviewer turnaround is typically 2-3 weeks per reviewer, but delays happen. If one reviewer is slow, the editor will usually wait rather than decide on incomplete feedback. This can extend the review phase to 6+ weeks.

What reviewers evaluate:

• Clinical significance: does this actually change practice?
• Methodological rigor: study design, statistical analysis, potential biases
• Ethical considerations: patient consent, trial registration, conflict disclosure
• Global relevance: does this matter beyond one healthcare system?
• Presentation quality: is the paper clearly written and well-structured?

Lancet decisions come faster than some journals but slower than NEJM (which targets 21 days). If you haven't heard anything after 8 weeks in review, a polite inquiry to the editorial office is reasonable.

After peer review, the Lancet editor will reach one of these decisions:

Accept (rare on first round). Fewer than 5% of papers are accepted without revision. If you get a clean accept, congratulations. It almost never happens.

Major revision. The most common positive outcome. Reviewers and editors want specific changes, additional analyses, or clarifications. Lancet revision requests are usually detailed and specific. Address every single point.

Reject after review. Even getting to review doesn't guarantee publication. Maybe 40-50% of reviewed papers ultimately get rejected. The editor's letter will usually explain what fell short.

If you get a revision invitation from the Lancet:

1. Respond to every point. Create a point-by-point response document. Don't skip anything, even if you disagree.
2. Be transparent about limitations. If you can't do what a reviewer asks (additional data, new analyses), explain why clearly.
3. Stick to the timeline. Lancet gives a revision deadline. Respect it. If you need an extension, ask early.
4. Don't add new data unnecessarily. Respond to what's asked. Adding unrequested analyses can complicate the re-review.
5. Highlight changes clearly. Track changes or a highlighted version makes re-review faster.

The Lancet's rejection rate after review is significant. Your paper was strong enough for review, which means it's competitive at other top journals:

The Lancet family: If the main journal rejects you, the editor may suggest a Lancet specialty journal. Lancet Oncology, Lancet Infectious Diseases, Lancet Respiratory Medicine, and Lancet Public Health are all high-impact in their own right. Take the suggestion seriously.

• 0-3 weeks under review: Don't contact the journal. This is normal.

• 4-6 weeks: Still normal. Peer review takes time.

• 6-8 weeks: A polite inquiry is appropriate: "I'm writing to inquire about the status of manuscript THELANCET-D-XXXX. Any update on expected timeline would be appreciated."
• 8+ weeks: Follow up again if you haven't heard back from the first inquiry.

• Lancet journal guide
• NEJM under review - comparing the NEJM process
• JAMA vs NEJM - the top two US clinical journals
• Acceptance rates across 50+ journals
• Review timelines compared

In our pre-submission review work with manuscripts targeting The Lancet, three failure patterns generate the most consistent desk rejections. We find these across manuscripts we've reviewed through our Lancet submission readiness check.

The trial with surrogate endpoints rather than clinical outcomes. The Lancet's editorial threshold is outcomes that matter to patients: survival, major morbidity, quality of life, or health system utilization. We observe that trials reporting a surrogate endpoint as the primary result, without demonstrating that the surrogate improvement correlates with the clinical outcome of interest, generate desk rejections citing insufficient clinical significance in the majority of cases. Including a pre-specified clinical outcome as the primary or key secondary endpoint substantially improves the desk-clearance rate.

The observational study with regional scope framed as globally applicable. The Lancet's readership is international and its editorial standard requires that findings be interpretable across healthcare systems. We observe that studies conducted in a single country or regional healthcare system that frame conclusions as globally applicable without discussing the generalizability of the findings generate desk rejections for scope mismatch. SciRev community data for The Lancet consistently identifies "limited generalizability beyond the study population" as a major concern on observational submissions. A clear discussion of how the healthcare context and population characteristics of the study compare to other settings prevents this desk rejection trigger.

The RCT where causal language in the abstract does not match the study design limitations. The Lancet editors evaluate whether the language in the abstract matches the evidentiary strength of the design. We observe that trials using causal verbs ("reduces," "prevents") without acknowledging known limitations (open-label design, short follow-up, selected population) generate requests for abstract revision. The fix is to match the claim strength to the design: "was associated with lower rates of" rather than "reduced" when the trial has limitations that prevent clean causal inference.